Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX vs FOLFOX-4 in 2nd-line mCRC
NCT00069108Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2003
- Primary completion
- Aug 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of capecitabine in metastatic colorectal cancer (mCRC), sponsored by Roche. Started Jul 2003; status: completed.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00069108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069108.